Refractory Chronic Lymphocytic Leukemia Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Active, not recruiting
  • Recurrent B-Cell Prolymphocytic Leukemia
  • +5 more
  • Palo Alto, California
  • +2 more
2022-04-05
Apr 5, 2022
N
Active, not recruiting
  • Ann Arbor Stage III Small Lymphocytic Lymphoma
  • +7 more
  • Washington, District of Columbia
  • +1 more
2022-04-05
Apr 5, 2022
U
Recruiting
  • Chronic Lymphocytic Leukemia
  • +4 more
    • Bobigny, France
    • +8 more
    2022-03-23
    Mar 23, 2022
    F
    Not yet recruiting
    • Recurrent Chronic Lymphocytic Leukemia
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    2022-03-31
    Mar 31, 2022
    M
    Active, not recruiting
    • Chronic Lymphocytic Leukemia
    • +5 more
    • Houston, Texas
      M D Anderson Cancer Center
    2022-03-15
    Mar 15, 2022
    M
    Recruiting
    • Recurrent Chronic Lymphocytic Leukemia
    • +4 more
    • Jacksonville, Florida
      Mayo Clinic in Florida
    2022-03-22
    Mar 22, 2022
    Z
    Recruiting
    • Relapsed Chronic Lymphocytic Leukemia
    • +4 more
    • Phoenix, Arizona
    • +6 more
    2022-03-21
    Mar 21, 2022
    F
    Terminated
    • Hematopoietic and Lymphoid Cell Neoplasm
    • +12 more
    • Laboratory Biomarker Analysis
    • ROR1 CAR-specific Autologous T-Lymphocytes
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    2022-03-07
    Mar 7, 2022
    M
    Not yet recruiting
    • Hematopoietic and Lymphoid Cell Neoplasm
    • +5 more
    • Houston, Texas
      M D Anderson Cancer Center
    2022-03-03
    Mar 3, 2022
    F
    Recruiting
    • Acute Leukemia
    • +18 more
    • Allogeneic Hematopoietic Stem Cell Transplantation
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    2022-03-16
    Mar 16, 2022
    U
    Recruiting
    • Recurrent Chronic Lymphocytic Leukemia
    • +17 more
    • Nivolumab
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    2022-02-28
    Feb 28, 2022
    C
    Active, not recruiting
    • Accelerated Phase Chronic Myelogenous Leukemia
    • +125 more
    • tetanus-CMV fusion peptide vaccine
    • laboratory biomarker analysis
    • Duarte, California
      City of Hope Medical Center
    2022-02-28
    Feb 28, 2022
    N
    Active, not recruiting
    • Glioma
    • +49 more
    • Duarte, California
    • +11 more
    2022-03-01
    Mar 1, 2022
    J
    Active, not recruiting
    • Prolymphocytic Leukemia
    • +4 more
    • Columbus, Ohio
    • +1 more
    2022-02-24
    Feb 24, 2022
    O
    Active, not recruiting
    • Contiguous Stage II Small Lymphocytic Lymphoma
    • +11 more
    • MOR00208
    • +2 more
    • Columbus, Ohio
      The Ohio State University Comprehensive Cancer Center
    2022-02-24
    Feb 24, 2022
    F
    Completed
    • CD19-Positive Neoplastic Cells Present
    • +12 more
    • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    2022-02-08
    Feb 8, 2022
    M
    Not yet recruiting
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +6 more
    • Chimeric Antigen Receptor T-Cell Therapy
    • +2 more
    • Rochester, Minnesota
      Mayo Clinic in Rochester
    2022-02-18
    Feb 18, 2022
    O
    Recruiting
    • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +58 more
    • Portland, Oregon
      OHSU Knight Cancer Institute
    2022-02-16
    Feb 16, 2022
    F
    Recruiting
    • Recurrent B-Cell Non-Hodgkin Lymphoma
    • +20 more
    • Chimeric Antigen Receptor T-Cell Therapy
    • +4 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    2022-01-24
    Jan 24, 2022
    V
    Recruiting
    • Relapsed Non Hodgkin Lymphoma
    • +6 more
    • Cincinnati, Ohio
    • +1 more
    2021-12-16
    Dec 16, 2021
    J
    Recruiting
    • Indolent B-Cell Non-Hodgkin Lymphoma
    • +18 more
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    2021-12-17
    Dec 17, 2021
    V
    Active, not recruiting
    • Blastoid Variant Mantle Cell Lymphoma
    • +8 more
    • Birmingham, Alabama
    • +4 more
    2021-11-09
    Nov 9, 2021
    V
    Withdrawn
    • Chronic Lymphocytic Leukemia
    • +8 more
    • Dose combination 1-1
    • +5 more
    • (no location specified)
    2021-11-01
    Nov 1, 2021